SCHEMBL6918474

SCHEMBL6918474

NCc1ccc(Nc2ncnc(-c3ccccc3C(F)(F)F)c2O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F9 P00740 3/20 0.57
F11 P03951 2/20 0.57
F7 P08709 2/20 0.57
CYP2C9 P11712 1/20 0.57
CYP3A4 P08684 8/20 0.46
CYP2D6 P10635 8/20 0.46
CYP2C19 P33261 8/20 0.46
CYP1A2 P05177 7/20 0.46
ALOX15 P16050 5/20 0.46
HSD17B10 Q99714 4/20 0.46
ALDH1A1 P00352 4/20 0.46
USP2 O75604 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
MAOB P27338 1/20 0.40
EPHX2 P34913 1/20 0.39
MAPK1 P28482 2/20 0.39
VCP P55072 1/20 0.38
F10 P00742 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9607623 0.91 F9 (0.57) F9F11F7CYP2C9CYP3A4
SCHEMBL15291870 0.78 F9 (0.87) F9F11F7CYP2C9F10
SCHEMBL6919134 0.74 F9 (0.68) F9F11F7CYP2C9F10
SCHEMBL6919891 0.74 F9 (0.58) F9F11F7CYP2C9MAPK1
SCHEMBL6918455 0.74 F9 (0.58) F9F11F7CYP2C9F10
SCHEMBL9607626 0.73 F9 (0.69) F9F11F7CYP2C9F10
SCHEMBL15291874 0.73 F9 (0.65) F9F11F7CYP2C9F10
SCHEMBL9607625 0.72 F9 (0.59) F9F11F7CYP2C9CYP3A4
SCHEMBL1233112 0.72 F9 (1.00) F9F11F7CYP2C9MAPK1
SCHEMBL6918977 0.72 F9 (0.77) F9F11F7CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462123-B1 4,5,6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2013-10-02 EP disclosed
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed
WO-2011017296-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS SCHERING CORPORATION (US) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS F9, F8, F12 F9 1/4885F11 5/4885F7 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.